 Corvus Pharmaceuticals, Inc. CRVS, a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, announced updated results from its Phase 1b2 clinical trial of ciforadenant, its adenosine A2A receptor antagonist, in patients with advanced refractory renal cell carcinoma RCC. The new data supports and refines the utility of the Adenosine Gene Signature AdenoSig, which was discovered by Corvus, as a predictive biomarker to identify RCC patients most likely to respond to treatment with ciforadenant. In the publication, for 30 patients with available tumor biopsies, AdenoSig positive patients had a 17 objective response rate ORR by RECIST criteria compared to 0 in AdenoSig negative patients. 